<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968341</url>
  </required_header>
  <id_info>
    <org_study_id>CINEBIOPHTA</org_study_id>
    <nct_id>NCT03968341</nct_id>
  </id_info>
  <brief_title>Study of Intraocular Concentrations (Aqueous Humor, Vitreous Humor) of Antibiotics After Local and/or Systemic Administration in Endophthalmitis</brief_title>
  <acronym>CINEBIOPHTA</acronym>
  <official_title>Intraocular Concentrations Study (Aqueous Humor, Vitreous Humor) of Antibiotics After Local and/or Systemic Administration in Endophthalmitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endophthalmitis is an intraocular inflammation due to a serious infection of bacterial,
      fungal or parasitic origin, involving visual prognosis if it is not treated in time and
      correctly. Despite the eye isolation from the rest of the body, germs can enter the eye
      either exogenously, during open globe surgery, following perforating eye trauma, or following
      anti-VEGF antibodies intravitreal injection, or other drugs such as corticosteroids for
      example, or by endogenous route, haematogenic as part of sepsis, usually during
      immunodepression. Post-operative endophthalmitis is the most feared complication following
      any endo-ocular surgery. It can be acute, occurring within 6 weeks post-operatively or
      delayed as after poor healing, or on a glaucoma filtration bubble. Endophthalmitis after
      cataract surgery is a complication with a low incidence of (0.030 to 0.047%) but which, due
      to interventions number carried out (830,000 in 2016, in France), appears significant. There
      are factors that favour endophtalmitis occurrence such as a vitreous exit from eyeball during
      surgical procedure, poor scar coaptation, premature removal of sutures, etc... They condition
      emergency care. Early diagnosis and appropriate treatment are essential for safeguarding the
      eye and its function. Therefore, therapeutic management requires endo-ocular sampling in
      front of any suspicion of endophtalmitis, to be done before any treatment, to carry out
      microbiological analysis (direct examination on slide, culture, universal and/or targeted
      PCR, antibiotic susceptibility test). Vitreous puncture is more contributive than anterior
      chamber puncture, underlining need for these two samples to identify the responsible germ.
      Once samples have been taken, a broad-spectrum antibiotic therapy introduction must be
      performed intra-vitreously combined with systemic and local administration. Intravitreal
      injections allow treatment to be provided at effective concentrations directly at the
      infection site. On the other hand, toxic risks must be taken into account, especially since
      the protocol may require multiple intravitreal injections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">August 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the concentrations of the various antibiotics in the media tested (aqueous and vitreous humours)</measure>
    <time_frame>48 hours</time_frame>
    <description>Determination of the concentrations of the various antibiotics in the media tested (aqueous and vitreous humours) by liquid chromatography coupled with a high-resolution mass spectrometer (HPLC-HRMS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of aqueous or vitreous humor samples collected by puncture from treated patients that can be used analytically</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Endophthalmitis</condition>
  <arm_group>
    <arm_group_label>intraocular antibiotic concentrations determination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the event that the patient develops unfavourably, the ophthalmologist include the patient in the trial.
The patient is reviewed at 48 hours after the introduction of probabilistic antibiotic therapy for clinical reassessment and the return of microbiological test results. Following this inclusion, the new samples will be taken when the patient passes through the operating room for the treatment of his pathology as part of the care. Ophthalmologists may have to adapt the patient's management (i.e. adjustment of antibiotic therapy) as part of their usual care routine. An anterior chamber puncture and a vitrectomy are performed. Eye fluids collected as part of the treatment are sent for analysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients</intervention_name>
    <description>A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.
Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information.</description>
    <arm_group_label>intraocular antibiotic concentrations determination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 18 years old

          -  Francophone

          -  Patients referred to emergencies by an ophthalmologist or doctor, or patients already
             hospitalized, with a unfavourable course 48 hours after introduction of broad spectrum
             probabilistic antibiotic therapy for the following situations:

               -  Cataract surgery

               -  Vitreoretinal surgery

               -  Intravitreal injection [anti-VEGF for the treatment of AMD, dexamethasone
                  (Ozurdex®) for the treatment of cystoid macular edema]

               -  Physical signs presence of intraocular inflammation (Tyndall, hypopyon, cyclic
                  membrane, hyalite)

               -  Presence of functional signs (Decreased Visual Acuity)

          -  Patients for whom a management re-evaluation is essential with obligation of new
             intraocular samples.

          -  Patient affiliated to social security or, failing that, to another health insurance
             system

        Exclusion Criteria:

          -  Patient under guardianship or curators

          -  Patient deprived of liberty

          -  Participation refusal in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François COUDORE, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Hospitalier Paris Saint Joseph</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François COUDORE, Professor</last_name>
    <phone>01 44 12 69 09</phone>
    <phone_ext>+33</phone_ext>
    <email>fcoudore@hpsj.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent BORDERIE, Professor</last_name>
    <email>vborderie@15-20.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BEAUSSIER Hélène, PhD, PharmD</last_name>
      <phone>+33 1 44 12 70 38</phone>
      <email>hbeaussier@hpsj.fr</email>
    </contact>
    <contact_backup>
      <last_name>CRC</last_name>
      <phone>+33 1 44 12 70 33</phone>
      <email>crc@hpsj.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Du DT, Wagoner A, Barone SB, Zinderman CE, Kelman JA, MaCurdy TE, Forshee RA, Worrall CM, Izurieta HS. Incidence of endophthalmitis after corneal transplant or cataract surgery in a medicare population. Ophthalmology. 2014 Jan;121(1):290-298. doi: 10.1016/j.ophtha.2013.07.016. Epub 2013 Aug 29.</citation>
    <PMID>23993357</PMID>
  </results_reference>
  <results_reference>
    <citation>Clarke B, Williamson TH, Gini G, Gupta B. Management of bacterial postoperative endophthalmitis and the role of vitrectomy. Surv Ophthalmol. 2018 Sep - Oct;63(5):677-693. doi: 10.1016/j.survophthal.2018.02.003. Epub 2018 Feb 15. Review.</citation>
    <PMID>29453989</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldschmidt P, Bensaid P, Semoun O, Chaumeil C. [Rational approach for the treatment of postoperative endophthalmitis in impoverished populations]. J Fr Ophtalmol. 2013 Mar;36(3):261-7. doi: 10.1016/j.jfo.2012.08.002. Epub 2013 Feb 11. French.</citation>
    <PMID>23410853</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar A, Sridhar MS, Dada T, Tewari HK, Gupta SK. Intravitreal pefloxacin therapy in postoperative endophthalmitis. Clin Exp Ophthalmol. 2000 Feb;28(1):38-40.</citation>
    <PMID>11345344</PMID>
  </results_reference>
  <results_reference>
    <citation>Khera M, Pathengay A, Jindal A, Jalali S, Mathai A, Pappuru RR, Relhan N, Das T, Sharma S, Flynn HW. Vancomycin-resistant Gram-positive bacterial endophthalmitis: epidemiology, treatment options, and outcomes. J Ophthalmic Inflamm Infect. 2013 Apr 22;3(1):46. doi: 10.1186/1869-5760-3-46.</citation>
    <PMID>23607574</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiquet C, Labetoulle M. [Fluoroquinolones in ophthalmology: indications and current use]. J Fr Ophtalmol. 2008 Oct;31(8):803-8. Review. French.</citation>
    <PMID>19107048</PMID>
  </results_reference>
  <results_reference>
    <citation>Adenis JP, Mounier M, Salomon JL, Denis F. Human vitreous penetration of imipenem. Eur J Ophthalmol. 1994 Apr-Jun;4(2):115-7.</citation>
    <PMID>7950335</PMID>
  </results_reference>
  <results_reference>
    <citation>Bowen RC, Zhou AX, Bondalapati S, Lawyer TW, Snow KB, Evans PR, Bardsley T, McFarland M, Kliethermes M, Shi D, Mamalis CA, Greene T, Rudnisky CJ, Ambati BK. Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol. 2018 Sep;102(9):1268-1276. doi: 10.1136/bjophthalmol-2017-311051. Epub 2018 Jan 11.</citation>
    <PMID>29326317</PMID>
  </results_reference>
  <results_reference>
    <citation>Cornut PL, Chiquet C. [Intravitreal injection of antibiotics in endophthalmitis]. J Fr Ophtalmol. 2008 Oct;31(8):815-23. French.</citation>
    <PMID>19107050</PMID>
  </results_reference>
  <results_reference>
    <citation>Gan IM, van Dissel JT, Beekhuis WH, Swart W, van Meurs JC. Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis. Br J Ophthalmol. 2001 Nov;85(11):1289-93.</citation>
    <PMID>11673290</PMID>
  </results_reference>
  <results_reference>
    <citation>Thompson AM. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol. 2007 Aug;35(6):566-77. Review.</citation>
    <PMID>17760640</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intraocular concentrations of antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

